HeartcoR Solutions, a prominent core laboratory specializing in the collection, evaluation, and reporting of cardiac safety and other physiological data in clinical research, has announced a major expansion of its remote monitoring technology offerings. By incorporating the TempTraq® device from Blue Spark Technologies, Inc. alongside the PCA 500 from QT Medical, the company is positioning itself as a fully integrated, one-stop partner for clinical trial sponsors seeking advanced monitoring tools.
Ciaran Cooper, Chief Executive Officer of HeartcoR Solutions, highlighted that meaningful progress in healthcare relies on demonstrating the safety and efficacy of both new therapies and medical technologies. By broadening its portfolio of monitoring solutions, HeartcoR is enabling trial sponsors to simplify operations, reduce the need for multiple vendor relationships, and streamline the sourcing of essential devices through a single trusted partner. This expansion is aimed at reducing inefficiencies, accelerating trial timelines, and strengthening the quality of data collected during the research process.
As the demand for patient-focused healthcare models increases, convenience and accessibility are becoming top priorities. Both pharmaceutical companies and medical device developers are adopting remote monitoring tools to obtain accurate and reliable data on how treatments and devices perform in real-world conditions. Market projections indicate that the global remote patient monitoring sector will expand at a CAGR of nearly 20% between 2025 and 2033, driven by a surge in new technologies ranging from home-based consumer devices to advanced clinical-grade systems. This growth highlights the importance of efficient device access, an area in which HeartcoR is expanding its role by offering a more comprehensive suite of solutions.
TempTraq®, developed by Blue Spark Technologies, is an FDA-cleared wearable that provides continuous, real-time temperature monitoring and integrates directly with clinical trial systems. The PCA 500, created by QT Medical, delivers a hospital-standard, 12-lead ECG in a format simple enough for patients to use at home or during trial visits, with secure cloud-based data management ensuring accuracy and compliance.
Cooper emphasized that HeartcoR’s mission is to support medical innovation by combining its expertise as a core laboratory with cutting-edge technologies designed to enhance patient experience and deliver consistent, reliable data. This expansion strengthens the company’s role in advancing clinical research by enabling more efficient, cost-effective, and patient-friendly trial designs.
